Loading news...
Shares of Milestone Scientific Inc. (NYSE: MLSS - Get Free Report) traded down 2.3% on Monday. The company traded as low as $0.2875 and last traded at $0.2969. 141,172 shares traded hands during mid-day trading, a decline of 62% from the average session volume of 371,079 shares. The stock had previously closed at $0.3038. Analysts
Pilot launched with six registered dental professionals; program expected to scale to 250 ambassadors over 12 months Pilot launched with six registered dental professionals; program expected to scale to 250 ambassadors over 12 months
Milestone Scientific Inc. (NYSE: MLSS - Get Free Report) shares shot up 3.1% during mid-day trading on Thursday. The stock traded as high as $0.3685 and last traded at $0.3551. 203,137 shares were traded during trading, a decline of 55% from the average session volume of 455,711 shares. The stock had previously closed at $0.3445.
Shares of Milestone Scientific Inc. (NYSE: MLSS - Get Free Report) dropped 1.6% during mid-day trading on Tuesday. The company traded as low as $0.2929 and last traded at $0.3070. Approximately 873,432 shares traded hands during mid-day trading, an increase of 89% from the average daily volume of 461,480 shares. The stock had previously closed
Milestone Scientific Inc. ( MLSS ) Q3 2025 Earnings Call November 14, 2025 8:30 AM EST Company Participants Eric Hines - Chief Executive Officer, President & Director Keisha Harcum - Vice President of Finance Conference Call Participants David Waldman - Crescendo Communications, LLC Anthony Vendetti - Maxim Group LLC, Research Division Bruce Jackson - The Benchmark Company, LLC, Research Division Presentation Operator Greetings, and welcome to the Milestone Scientific Third Quarter 2025 Financial Results and Business Update Call. [Operator Instructions] And please note, this conference is being recorded.
ROSELAND, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced financial results and provided a business update for the third quarter ended September 30, 2025, highlighting continued progress on the Company's transformation and growth initiatives.
ROSELAND, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Friday, November 14th, 2025, to discuss the company's financial results for the third quarter ended September 30, 2025, as well as the company's corporate progress and other developments.
Company outlines decisive initiatives to strengthen its dental and medical businesses, reduce operating expenses across the organization, and position Milestone Scientific for accelerated growth and improved financial performance Company outlines decisive initiatives to strengthen its dental and medical businesses, reduce operating expenses across the organization, and position Milestone Scientific for accelerated growth and improved financial performance
Notification has no immediate effect on the Company's listing or day-to-day operations Notification has no immediate effect on the Company's listing or day-to-day operations
Appointment strengthens Board expertise as Milestone Scientific drives commercial expansion and payer adoption of CompuFlo® in interventional pain management Appointment strengthens Board expertise as Milestone Scientific drives commercial expansion and payer adoption of CompuFlo® in interventional pain management
Expands senior leadership team and board of directors to support next phase of growth Expands senior leadership team and board of directors to support next phase of growth
ROSELAND, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:00 AM Eastern Time on Friday, August 15th, 2025, to discuss the company's financial results for the second quarter ended June 30, 2025, as well as the company's corporate progress and other developments.
ROSELAND. N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Jason Papes as Senior Vice President, Global Head of Sales and Marketing, effective immediately.
Seasoned executive with proven track record driving growth and building customer focused teams to lead Milestone's next phase of commercial execution Seasoned executive with proven track record driving growth and building customer focused teams to lead Milestone's next phase of commercial execution
ROSELAND, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the initiation of commercial sales of its CompuFlo® Epidural System and related disposables at The Painless Center, located in Tenafly, New Jersey.
Brings Proven Commercial Leadership, Reimbursement Expertise, and Global Market Insight to Support Next Phase of Growth Across Medical and Dental Segments Brings Proven Commercial Leadership, Reimbursement Expertise, and Global Market Insight to Support Next Phase of Growth Across Medical and Dental Segments
ROSELAND, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and reported financial results for the first quarter ended March 31, 2025.
Dr. Roman Kosiborod, DO to Utilize CompuFlo® for Enhanced Precision in Pain Management Procedures Dr. Roman Kosiborod, DO to Utilize CompuFlo® for Enhanced Precision in Pain Management Procedures
Dr. Ilana Etelzon Integrates CompuFlo® Epidural System into Practice Following Positive Clinical Experience Dr. Ilana Etelzon Integrates CompuFlo® Epidural System into Practice Following Positive Clinical Experience
Reports Expanding Adoption of CompuFlo® Epidural System Following Previously Announced Medicare Price Assignment Reports Expanding Adoption of CompuFlo® Epidural System Following Previously Announced Medicare Price Assignment